NASDAQ:EYEN
Eyenovia Inc. Stock News
$0.87
+0.0506 (+6.21%)
At Close: May 08, 2024
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
10:31am, Tuesday, 09'th Apr 2024
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript
08:52pm, Monday, 18'th Mar 2024
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
06:21pm, Monday, 18'th Mar 2024
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
07:00am, Monday, 11'th Mar 2024
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
US FDA approves Eyenovia's eye drug, Formosa Pharma says
06:08pm, Monday, 04'th Mar 2024
The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.
Eyenovia: Racing Toward The Finish Line
02:45pm, Monday, 26'th Feb 2024
Eyenovia has received FDA approval for its Optejet system, which revolutionizes how eye medications are dosed, resolving limitations and adverse events caused by traditional eye droppers. The company'
7 Promising Penny Stocks With the Potential to Defy Expectations
08:17am, Friday, 15'th Dec 2023
You know you want it. High-potential penny stocks that is.
Eyenovia, Inc. (EYEN) Q3 2023 Earnings Call Transcript
09:34pm, Monday, 13'th Nov 2023
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Glenn Garmont - LifeSci Partners, IR Michael Rowe - Chief Executive Officer John Gandol
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
08:16am, Thursday, 09'th Nov 2023
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
08:00am, Monday, 06'th Nov 2023
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
7 Penny Stocks To Buy Now According To Analysts, Targets Up To 751%
11:32am, Thursday, 02'nd Nov 2023
The penny stock market is an enticing yet volatile landscape for investors seeking big rewards. While the chance to uncover the next hidden gem before it rockets higher is enticing.
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
07:00am, Monday, 09'th Oct 2023
In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
08:00am, Thursday, 21'st Sep 2023
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for
Eyenovia: It Is Now Time To See Positive Results In Their Marketing Efforts
05:08pm, Monday, 28'th Aug 2023
Eyenovia has obtained the first required state pharmacy license from New York, allowing them to obtain the first commercial sale of their drug candidate MydCombi. The company has conducted training se
Eyenovia, Inc. (EYEN) Q2 2023 Earnings Call Transcript
09:24am, Sunday, 13'th Aug 2023
Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Eric Ribner - Investor Relations Michael Rowe - Chief Executive Officer John Gandolfo - C
